RespireRx Pharmaceuticals Inc.
RSPI · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $430 | $702 | $638 | $599 |
| G&A Expenses | $1,150 | $1,857 | $2,677 | $1,137 |
| SG&A Expenses | $1,150 | $1,857 | $2,677 | $1,137 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,579 | $2,559 | $3,315 | $1,737 |
| Operating Income | -$1,579 | -$2,559 | -$3,315 | -$1,737 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$523 | -$586 | -$986 | -$379 |
| Pre-Tax Income | -$2,103 | -$3,145 | -$4,301 | -$2,115 |
| Tax Expense | -$80 | $725 | $546 | $0 |
| Net Income | -$2,103 | -$3,870 | -$4,847 | -$2,520 |
| % Margin | – | – | – | – |
| EPS | -0.036 | -0.04 | -0.22 | -6.45 |
| % Growth | 10.5% | 81.9% | 96.6% | – |
| EPS Diluted | -0.036 | -0.04 | -0.22 | -6.45 |
| Weighted Avg Shares Out | 111,323 | 88,347 | 25,856 | 391 |
| Weighted Avg Shares Out Dil | 111,323 | 88,347 | 25,856 | 391 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $604 | $725 | $546 | $405 |
| Depreciation & Amortization | -$152 | $2,559 | $0 | $1,737 |
| EBITDA | -$1,651 | $139 | -$3,756 | $26 |
| % Margin | – | – | – | – |